Startups channel feed – Endpoints News

Startups channel feed

Cambridge spinout grabs $23M round to launch a new campaign to tackle protein misfolding

7 years ago

Computational scientists design a new IL-2 cancer drug and spin it out into a biotech startup

7 years ago

Betting on allosteric mutations driving cancer, Black Diamond raises $85M in fresh round

7 years ago

How to build a biotech unicorn: Get the star team in place, attract deep-pocket VCs, paint a big picture and raise up to $1B

7 years ago

Juno founders set their sights on creating an ‘epic’ new biotech with high-rolling investors at their back

7 years ago

With early-stage studies underway, Connect Biopharmaceuticals closes $55M round to advance immune modulators

7 years ago

Why did Liz Barrett turn her back on a top job at Novartis in exchange for the helm of a biotech you never heard of?

7 years ago

The year of living large: A fledgling Relay Therapeutics reaps a whopping $400M venture round, with SoftBank pointing the way to a windfall

7 years ago

Little Tetra is prepping a PhII Alzheimer’s study. In fact, they just got $40M to fund it

7 years ago

Targeting underlying cause of PAH, Cambridge spinout Morphogen-IX raises about $23M in Series B

7 years ago

Entrada launches today, taking a $59M shot at some tough intracellular targets

7 years ago

Jonathan Lim isn't ready to say much about his new startup, but he does have $42M for it

7 years ago

Harvard prof Omid Farokhzad heads west, setting up a new Bay Area biotech on a mission to start a revolution in pre-symptomatic disease detection

7 years ago

Black Diamond turns down an open stretch of R&D highway, headed to a showdown with oncogenes

7 years ago

Sue Dillon, Karyn O'Neil steer fledgling Aro Biotherapeutics to $13M debut — with J&J's blessing

7 years ago

Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and β-thalassemia

7 years ago

Novartis-backed Inflazome raises $46M for their clinical challenge to prove NLRP3 is a great anti-inflammatory target

7 years ago

With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A funding

7 years ago

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline

7 years ago

Penn spinout preps for human studies of a new-model CAAR, aiming at a one-time cure for autoimmune diseases

7 years ago

The resurrection of LUM001: Mike Grey gets his drug back from Shire — along with $120M to gamble on PhIII trials

7 years ago

Omeicos scores $19.5M in Series C to take its omega-3 drug to the next round

7 years ago

Tuning in: Intensity's immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon

7 years ago

Carving a pipeline out of troubled Teva, OrbiMed leads $60M launch of new NASH player

7 years ago

First page Previous page 60 61 626364 65 66 Next page Last page